In a regulatory filing , Vanda Pharmaceuticals ( VNDA ) discloses that it has filed a patent infringement suit against Roxanne Laboratories' ANDA for generic versions of iloperidone
Top 10 Gainers: LSBI +39% . NQ +35% . THRD +31% . VNDA +24% . DRWI +22% . CLDN +21% . PL +18% . EGLE +13% . DRL +12% . HOTR +12% . Top 10 Losers: TSPT -34% . EBIX
Shares of Vanda Pharmaceuticals ( VNDA +21.4% ) pop on increased volume in response to yesterday's announcement that the EMA accepted its MAA for Hetlioz. Post your comment!
Gainers: NQ +31% . PL +18% . DRWI +16% . VNDA +10% . SPWR +5% . Losers: FCEL -14% . TIBX -12% . JKS -8% . YGE -7% . TSL -6% . BLDP -5% . CSIQ -5% . Post your comment!
The European Medicines Agency accepts Vanda Pharmaceuticals ' ( VNDA ) Marketing Authorization Application for Hetlioz ( tasimelteon ) for the treatment of non-24-hour sleep-wake disorder
Vanda Pharmaceuticals reported first-quarter results were below our expectations because of significantly higher-than-anticipated operating costs
outstanding, which should help ensure that his interests are well aligned with those of other shareholders. Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its key
We're raising our fair value estimate for Vanda VNDA to $10 per share, following the announcement that orphan sleep disorder drug tasimelteon has gained priority review designation
(Reuters) - Shares of Vanda Pharmaceuticals Inc jumped nearly 42 percent on expectations that its sleep disorder drug could reach market earlier than expected after U.S. health regulators said it...
Vanda VNDA reported first-quarter results that matched our expectations for continued stagnant Fanapt growth, countered by lowered operating